The United Kingdom and the United States have signed a key trade agreement that will maintain zero import taxes on British pharmaceutical shipments going into the American market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to raise funding on pharmaceuticals through the NHS. This move ensures that import taxes on these vital goods will stay at nothing for a duration of the next three years.
This development follows previous threats to dramatically increase duties on branded drug imports, with potential rates floated up to 100%.
"This agreement with the United Kingdom reinforces the international landscape for cutting-edge drugs and brings much-needed fairness to U.S.–U.K. drug exports," a release said.
Economic Impact
Drugs constitute one of the UK's biggest exports to the US, which is by far the largest destination for large British pharmaceutical firms.
Export figures indicate that in the one-year period to the end of last September, the UK sold medicines valued at billions to the US. This amount accounted for a significant portion of British export trade in that period.
"This deal secures jobs, boosts investment and paves the way for the UK to emerge as a international leader for biotech and pharma," a minister stated.
Specific UK Commitments
The pact entails several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to increase overall health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The sum drug companies must return to the NHS to stay within budget will be limited at 15%. Last year, repayments were more than twenty percent.
Broader Context
This agreement takes place against a ongoing dispute between the sector and the UK government over medicine costs and NHS adoption.
This friction were exacerbated by claims that US patients were charged several times more for the identical medicines than consumers in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been paused or scrapped, while substantial funding commitments have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had decreased as a share of its overall budget over the last ten years.
